CORRESP Filing
Contineum Therapeutics, Inc.
Date: May 21, 2025 · CIK: 0001855175 · Accession: 0001437749-25-018028
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287275
Letter
ctnm20250520_corresp.htm
Contineum Therapeutics, Inc.
3565 General Atomics Court, Suite 200
San Diego, California 92121
May 21, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re:
Contineum Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 14, 2025
File No. 333-287275
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on May 23, 2025, or as soon thereafter as is practicable.
The Registrant hereby authorizes Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.
Thank you for your assistance. If you should have any questions, please contact Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8046.
Very truly yours,
Contineum Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm ctnm20250520_corresp.htm Contineum Therapeutics, Inc. 3565 General Atomics Court, Suite 200 San Diego, California 92121 May 21, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Contineum Therapeutics, Inc. Registration Statement on Form S-3 Filed May 14, 2025 File No. 333-287275 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on May 23, 2025, or as soon thereafter as is practicable. The Registrant hereby authorizes Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration. Thank you for your assistance. If you should have any questions, please contact Ryan Gunderson of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, counsel to the Registrant, at (858) 436-8046. Very truly yours, Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Contineum Therapeutics, Inc. cc: Carmine Stengone, President, Chief Executive Officer and Director, Contineum Therapeutics, Inc. John Healy, General Counsel, Contineum Therapeutics, Inc. Jeffrey C. Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Ryan Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP John E. Maciejewski, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP